Peptide Surf a research-only wiki of supplements & peptides
Research & educational use only. This site catalogs published research and public commentary about supplements and peptides. It is not medical advice and not a recommendation to use any compound. Consult a qualified clinician.
← Catalog

Semaglutide

peptide Metabolic & Weight Management

A long-acting synthetic analog of the incretin hormone GLP-1. Native GLP-1 is released after eating and signals satiety but degrades within minutes; semaglutide persists for days, supporting weekly dosing for appetite reduction and weight loss. FDA-approved (Ozempic / Wegovy / Rybelsus).

Synonyms

Ozempic · brand Wegovy · brand Rybelsus · brand GLP-1 receptor agonist · other GLP-1 analog · other

Synonyms drive on-site search and are used to index ingested research papers and tweets to this page.

Safety

Contraindications

  • Personal/family history of medullary thyroid carcinoma or MEN 2
  • History of pancreatitis (discuss with a clinician)

Reported side effects

  • Nausea, vomiting, constipation or diarrhea
  • Reduced appetite

FDA-approved and studied in large trials. This page summarizes public information and commentary and is not medical advice.

Protocols

No structured protocols recorded.

Claims & evidence

Reduces appetite and produces clinically significant weight loss via GLP-1 receptor agonism.

Weight loss positive meta-analysis

Notes

Overview

Semaglutide is the prototypical GLP-1 receptor agonist behind the current metabolic-medicine wave. Its long half-life is the key pharmacologic difference from endogenous GLP-1.